CTS (CTS) Q3 2026 Earnings Call Transcript

CTS reported Q3 2026 revenue of $149.6 million, up 5% year over year, with record adjusted gross margin of 42.2% and adjusted diluted EPS of $0.77, versus $0.60 a year earlier. It raised full-year 2026 revenue guidance to $580 million–$590 million and adjusted diluted EPS guidance to $2.78–$2.88; the company also completed a $50 million cash acquisition of Millar, which management expects to contribute approximately $30 million in annual revenue and become EPS-accretive in the second half of 2027. Management cautioned that profitability may normalize from the quarter’s unusually favorable mix, while forecasting flat-to-modestly lower global light vehicle production.

Analysis

CTS’s raised outlook is positive, but the quality of the Q3 earnings beat is less durable than the headline margin suggests. Management attributed part of the margin step-up to unusually favorable project mix and about $1.4 million of FX benefit; FX also added roughly $0.04 to quarterly EPS—about 5% of reported EPS. That makes normalization a near-term earnings risk even if underlying execution remains sound. The key cross-check is orders: diversified book-to-bill is healthy, but medical’s 0.66 contrasts with its strong reported growth, leaving the durability and timing of that growth less certain. A&D’s 1.91 ratio supports visibility, not immediate conversion: government funding and percentage-of-completion accounting can make quarterly revenue lumpy.

Over 1–3 months, the market is likely to test whether guidance can hold as mix and FX tailwinds fade. Over 6–18 months, Millar could improve CTS’s medical exposure and broaden its sensing capabilities, but the company expects EPS accretion only in H2 2027 and says initial EBITDA contribution may not be accretive. The $50 million cash price is about 1.7x stated annual revenue; without Millar’s margins, growth, and retention data, that is not evidence by itself of an attractive deal. The contrarian angle is that portfolio diversification may improve earnings resilience, while near-term EPS quality and medical order timing remain underappreciated risks. No valuation or post-release price data were provided, so do not assume the stock is cheap or the initial reaction is mispriced.

Key Decisions for Investors

• Avoid chasing the earnings reaction. Consider a staged CTS long only if the stock gives back some initial strength while 2026 guidance remains intact; reassess if management cuts the $2.78–$2.88 EPS range.
• For the next 1–3 months, track gross-margin normalization and the medical book-to-bill. A sustained medical ratio below 1 alongside weaker medical revenue would challenge the growth thesis; improving orders would support it.
• Treat A&D bookings as a visibility indicator, not a near-term revenue forecast. Watch government funding, backlog conversion, and whether the elevated A&D book-to-bill translates into reported sales over coming quarters.
• Keep Millar and turbo-actuator upside in the 6–18-month catalyst bucket, not the current-quarter thesis. Verify Millar’s standalone margins and growth, integration progress, and the timing of platform approvals before assigning material earnings value.